Teva scores European patent victory for long-acting Copaxone

Carly Helfand After fighting a long battle over the IP shield on lead drug Copaxone, Teva is feeling the heat from generics makers over the patent on its new, long-acting ...

Valeant weighs Paragon sale to get out of FTC spotlight

Carly Helfand The Federal Trade Commission has been investigating Valeant for potentially cornering a piece of the contact lens market–and now, the Canadian drugmaker ...

Mesoblast disappoints in another below-the-range biotech IPO

Damian Garde Australian biotech Mesoblast priced its U.S. IPO below expectations, raising $ 60 million to support its pipeline of cell therapies. FierceBiotech News

Bloomberg: Valeant had planned to expand Philidor relationship before scandal hit

Tracy Staton Valeant Pharmaceuticals disowned its Philidor specialty pharmacy fairly quickly after major questions arose about their relationship. But till those concerns went public, ...

GlaxoSmithKline bags an FDA OK for its asthma drug with eyes on a respiratory turnaround

Damian Garde GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drugmakers at work on similar therapies as it seeks to bolster its respiratory ...

Voyager spells out its $92M IPO pitch as Wall Street sours on biotech

Damian Garde Gene therapy developer Voyager Therapeutics is angling for as much as $ 92 million in a planned IPO, braving choppy waters for biotech after a string of disappointing ...

AstraZeneca’s gout drug wins faint praise from FDA advisers

Damian Garde A majority of independent FDA advisers recommended approval for AstraZeneca's new gout drug, but not without noting that the treatment's safety profile presents ...

FDA finds mystery ‘deficiencies’ with Neos’ long-acting Ritalin on the eve of approval

Damian Garde Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's ...

Pharma’s newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses

Eric Palmer If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

Takeda gets enough takers to complete $2.3B Actos settlement

Eric Palmer A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $ 2.3 billion offer to settle thousands of claims over the cancer risks ...

FierceBiotech radio on GSK’s latest setback, Kyle Bass’ ‘truthful irrelevancy,’ and Horizon’s web presence

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS